- IMIDAZOLE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF
-
Disclosed are imidazole derivatives as represented by formula (I), and preparation method and use thereof. The compounds can inhibit cyclooxygenase and treat diseases mediated by cyclooxygenase.
- -
-
Paragraph 0282; 0284
(2013/09/12)
-
- Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists
-
GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119
- Katamreddy, Subba R.,Carpenter, Andrew J.,Ammala, Carina E.,Boros, Eric E.,Brashear, Ron L.,Briscoe, Celia P.,Bullard, Sarah R.,Caldwell, Richard D.,Conlee, Christopher R.,Croom, Dallas K.,Hart, Shane M.,Heyer, Dennis O.,Johnson, Paul R.,Kashatus, Jennifer A.,Minick, Doug J.,Peckham, Gregory E.,Ross, Sean A.,Roller, Shane G.,Samano, Vicente A.,Sauls, Howard R.,Tadepalli, Sarva M.,Thompson, James B.,Xu, Yun,Way, James M.
-
p. 10972 - 10994
(2013/02/25)
-
- GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
-
The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
- -
-
Page/Page column 165
(2010/11/29)
-
- Amide compounds and medications containing the same technical field
-
The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group,Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring,X represents —NH—, an oxygen atom or a sulfur atom,Y represents —NR4—, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone,Z represents a single bond or —NR5—,R4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group,R5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, andn is integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at one of these compounds.
- -
-
Page/Page column 145
(2010/02/10)
-
- p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents
-
This invention relates to anti-inflammatory and analgesic compounds, especially to certain p-(sulfonyl)phenyl amino derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
- -
-
-
- Imidazopyridazines. XII. Syntheses and Central Nervous System Activities of Some Substituted Imidazopyridazines and Related Imidazopyridines, Imidazopyrimidines and Imidazopyrazines
-
Syntheses are reported for some 6-chloro(alkoxy, alkylthio and phenylthio)-3-benzamidomethyl-(acetamidomethyl and methoxy)-2-arylimidazopyridines and some corresponding imidazo-pyridazines, imidazopyrimidines and imidazopyrazines.IC50 values (or percentage displacement) are reported and discussed for the displacement of 3H>diazepam from rat brain membrane by each of these compounds.The imidazopyridines were generally less potent than the imidazopyridazines but considerably more potent than the corresponding imidazopyrimidines or imidazopyrazines.Substitution of 2-aryl group by a 2-alkyl group in imidazopyridazines led to a significant loss of activity.
- Barlin, Gordon B.,Davies, Les P.,Ireland, Stephen J.,Ngu, Maria M. L.,Zhang, Jiankuo
-
p. 877 - 888
(2007/10/02)
-
- Substituted imidazolo-pyridines and method
-
Imidazolo-pyridine derivatives are provided having the structure STR1 wherein R is lower alkyl, lower alkenylalkyl, lower alkynylalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl or phenylalkyl and R1 is lower alkyl, phenylalkyl or di-lower alkylaminoalkyl and n is 0, 1 or 2. These compounds are useful as anthelmintic agents administered orally or parenterally.
- -
-
-
